Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics (STARRING)

Sanquin Research & Blood Bank Divisions

Status: Unknown

Conditions: Sickle Cell Disease; Alloimmunization

Study type: Observational

Funder types: Other

Identifiers

NCT03288012

NL60834.018.17

Details and patient eligibility

About

The focus of the study is the pathophysiological mechanism of allo-antibody formation after red blood cell transfusion in sickle cell disease patients.

Full description

The main objectives of this study are to study the role of the innate and adaptive immune response in allo-antibody formation and furthermore to identify the genetic and time dependent clinical risk factors on alloimmunization in SCD patients.

Subjects without allo-antibodies, receiving a red blood cell transfusion, will be included in this study. At 5 time points blood will be drawn from these subjects. (T0: Before transfusion, T1: 1 day after transfusion, T2: 1 week after transfusion, T3: 4 weeks after transfusion, T4: 6 months after transfusion).

At each time point specific markers of the immune system will be measured.

Enrollment: 150 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Sickle cell disease
• Receiving a red blood cell transfusion

Exclusion criteria

• Previous positive screen for allo-antibodies
• >25 red blood cell units in the past